Symbol="CRNX"
AssetType="Common Stock"
Name="Crinetics Pharmaceuticals Inc"
Description="Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California."
CIK="1658247"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1100512000"
EBITDA="-181007008"
PERatio="None"
PEGRatio="None"
BookValue="5.19"
DividendPerShare="0"
DividendYield="0"
EPS="-3.34"
RevenuePerShareTTM="0.08"
ProfitMargin="0"
OperatingMarginTTM="-42.48"
ReturnOnAssetsTTM="-0.351"
ReturnOnEquityTTM="-0.601"
RevenueTTM="4285000"
GrossProfitTTM="-125488000"
DilutedEPSTTM="-3.34"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.144"
AnalystTargetPrice="46.89"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="171.68"
PriceToBookRatio="2.49"
EVToRevenue="99.87"
EVToEBITDA="-3.393"
Beta="0.861"
num_52WeekHigh="24.58"
num_52WeekLow="15.23"
num_50DayMovingAverage="20.87"
num_200DayMovingAverage="18.73"
SharesOutstanding="54026000"
DividendDate="None"
ExDividendDate="None"
symbol="CRNX"
open="20.43"
high="20.50"
low="19.95"
price="20.37"
volume="493039.00"
latest_trading_day="2023-07-14"
previous_close="20.48"
change="-0.11"
change_percent="-0.5371%"
aroon_positive_momentum_days="72"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="72"
Volume_recent_avg="444660"
Change_recent_avg="-0.04"
Delta_recent_avg="0.9"
Variance_recent_avg="0.45"
Change_ratio_recent_avg="-0.27"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="72"
Aroon_momentum_negative="28"
image_negative_thumbnail_id_1="1151"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0184.jpeg"
image_negative_thumbnail_id_2="1153"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0186.jpeg"
image_neutral_thumbnail_id_1="553"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_neutral_thumbnail_id_2="593"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0006.jpeg"
image_positive_thumbnail_id_1="960"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0122.jpeg"
image_positive_thumbnail_id_2="689"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0019.jpeg"
image_professor_thumbnail_id_1="1199"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
